ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021
Atrial Fibrillation in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.Journal of the American College of Cardiology · 2024Guideline
- Guideline
- Atrial Fibrillation Following Autologous Stem Cell Transplantation in Multiple Myeloma: Incidence, Predictors, and Prognostic Impact.JACC. CardioOncology · 2026Article
- Atrial fibrillation post hematopoietic stem cell transplant: incidence, risk factors, and management challenges.Frontiers in cardiovascular medicine · 2026Review
- Cardiovascular and Oncologic Considerations in Adult Hodgkin Lymphoma: JACC: CardioOncology State-of the-Art Review.JACC. CardioOncology · 2025Review
- Presence of Clonal Hematopoiesis and Cardiac Events After Allogeneic Stem Cell Transplantation.Journal of the American Heart Association · 2025Article
- Atrial fibrillation or flutter in patients undergoing stem cell transplantation, in-hospital and post-discharge outcomes in a large nationwide sample across the United States.Cardio-oncology (London, England) · 2025Article
- Challenges and Opportunities in the Care of Hematopoietic Cell Transplant Survivors in the Modern Era.Advances in experimental medicine and biology · 2025Review
- Clinical Outcomes in Hospitalized Patients with Cancer and New versus Preexistent Atrial Fibrillation.European heart journal. Quality of care & clinical outcomes · 2024Article
- Artificial intelligence enabled interpretation of ECG images to predict hematopoietic cell transplantation toxicity.Blood advances · 2024Article
- Atrial arrhythmias following CAR-chimeric antigen receptor T-cell therapy: Incidence, risk factors and biomarker profile.British journal of haematology · 2024Article
- Cardiovascular Considerations in Patients Undergoing Hematopoietic Cell Transplantation.Current treatment options in oncology · 2024Review
- Cardiovascular Disease After Hematopoietic Stem Cell Transplantation in Adults:JACC. CardioOncology · 2024Review
- Article
- Coexisting atrial fibrillation and cancer: time trends and associations with mortality in a nationwide Dutch study.European heart journal · 2024Article
- Association of atrial fibrillation and outcomes in patients undergoing bone marrow transplantation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023Article
- Atrial Fibrillation and Cancer Patients: Mechanisms and Management.Current cardiology reports · 2022Review
- Life expectancy and burden of late complications after reduced intensity conditioning allogeneic transplantation.Bone marrow transplantation · 2022Article
- Chemotherapy-Free Targeted Anti-BCR-ABL+ Acute Lymphoblastic Leukemia Therapy May Benefit the Heart.Cancers · 2022Article
- Atrial fibrillation in older adults with cancer.Journal of geriatric cardiology : JGC · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
purposeTo examine the incidence and risk factors for de novo atrial fibrillation (AF) after allogeneic hematopoietic cell transplantation (HCT) and to describe the impact of AF on HCT-related outcomes.
methodsA retrospective cohort study design was used to examine AF and associated outcomes in 487 patients who underwent allogeneic HCT from 2014 to 2016 and to characterize patient- and HCT-related risk factors. A nested case-control study design was used to describe the association between pre-HCT echocardiographic measures and future AF events.
resultsThe median age at HCT was 52.4 years (18.1-78.6); the median time to AF was 117.5 days (4.0-1,405.0). The 5-year cumulative incidence of AF was 10.6%. Older (≥ 50 years) age (hazard ratio [HR], 2.76; 95% CI, 1.37 to 5.58), HLA-unrelated donor (HR, 2.20; 95% CI, 1.18 to 4.12), dyslipidemia (HR, 2.40; 95% CI, 1.23 to 4.68), and pre-HCT prolonged QTc interval (HR, 2.55; 95% CI, 1.38 to 4.72) were independent risk factors for AF. Despite having comparable left ventricular systolic function, patients who developed AF were significantly more likely to have lower left atrial ejection fraction, left atrial reservoir function, and elevated tricuspid regurgitant jet velocity prior to HCT, compared with patients who did not. The incidence rate of stroke after AF was 143 per 1,000 person-years. In adjusted analyses, AF was associated with a 12.8-fold (HR, 12.76; 95% CI, 8.76 to 18.57) risk of all-cause mortality and 15.8-fold (HR, 15.78; 95% CI, 8.70 to 28.62) risk of nonrelapse mortality.
conclusionThe burden of AF after allogeneic HCT population is substantial, and the development of AF is associated with poor survival. We identified important associations between patient demographics, pre-HCT cardiac parameters, HCT-related exposures, and risk of AF, setting the stage for targeted prevention strategies during and after HCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.